Do older and younger patients derive similar survival benefits from novel oncology drugs? A systematic review and meta-analysis | Zendy

Vanessa Sarah Arciero | Zendy; Sierra Cheng | Zendy; Robert M. Mason | Zendy; Erica McDonald | Zendy; Ronak Saluja | Zendy; Kelvin Chan | Zendy

Open Access

Do older and younger patients derive similar survival benefits from novel oncology drugs? A systematic review and meta-analysis

Author(s) -

Vanessa Sarah Arciero,

Sierra Cheng,

Robert M. Mason,

Erica McDonald,

Ronak Saluja,

Kelvin Chan

Publication year - 2018

Publication title -

age and ageing

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.014

H-Index - 143

eISSN - 1468-2834

pISSN - 0002-0729

DOI - 10.1093/ageing/afy079

Subject(s) - medicine , hazard ratio , meta analysis , confidence interval , clinical trial , oncology , clinical endpoint , subgroup analysis , randomized controlled trial

older patients are commonly believed to derive less benefit from cancer drugs, even if they fulfil clinical trial eligibility [Talarico et al. (2004, J Clin Oncol, 22(22):4626-31)]. We aim to examine if novel oncology drugs provide differential age-based treatment outcomes for patients on clinical trials.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research